Tübingen, Germany-based CureVac, a biopharmaceutical company developing transformative medicines based on mRNA, announced on Tuesday, February 7, the price of 27,027,028 common shares in an underwritten public offering at a public offering price of $9.25 per share for gross proceeds of approximately $250M.
The German company has granted the underwriters a 30-day option to purchase up to an additional 4,054,054 common shares (15 per cent of the number of common shares) to be sold in the offering on the same terms and conditions.
“All of the shares in the offering are to be sold by CureVac N.V,” says the company.
The offering is expected to close on or about February 10, 2023, subject to customary closing conditions, says the company.